Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Virtual Congress 2020

ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer

Emerging systemic therapies in unresectable bladder cancer: Immunotherapy, kinase inhibitors and antibody-drug conjugates

Date

21 Nov 2020

Session

ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer

Topics

Immunotherapy

Tumour Site

Urothelial Cancer;  Prostate Cancer

Presenters

Matthew Galsky

Authors

M. Galsky

Author affiliations

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, 10029 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Q&A, live discussion and wrap up

Presenter: Ravindran Kanesvaran

Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.